Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

By R. Larson, Brian J. Druker, F. Guilhot, S. O’Brien, G. Rivière, T. Krahnke, I. Gathmann, Yanfeng Wang. Blood, 2008

654 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/5177fff9f30f8bb780579ee5c0732e2b5232965a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. J. Goldman
2. J. Apperley
3. Brian J. Druker

Citations in the corpus

• Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (2010, methodology): “We also considered clinical variables previously shown to predict response together with other factors identified more recently (ie, expression of human organic cation transporter-1 [hOCT1],(17,18) polymorphisms in multidrug resistance gene-1 [MDR1, or ABCB1],(19) mutations in the tyrosine kinase do”